Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This study was designed to find the most effective and safest doses of both HYCAMTIN and
CARBOPLATIN that can be given for the treatment of ovarian cancer. This study may allow
researchers to determine the effectiveness of combining HYCAMTIN and CARBOPLATIN.